Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Dec 1;74(12):3555-3564.
doi: 10.1093/jac/dkz347.

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

Kristen Andreatta  1 , Madeleine Willkom  1 , Ross Martin  1 , Silvia Chang  1 , Lilian Wei  1 , Hui Liu  1 , Ya-Pei Liu  1 , Hiba Graham  1 , Erin Quirk  1 , Hal Martin  1 , Kirsten L White  1
Affiliations
Clinical Trial

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

Kristen Andreatta et al. J Antimicrob Chemother. .

Erratum in

Abstract

Objectives: Studies 1878 and 1844 demonstrated non-inferior efficacy of switching suppressed HIV-1-infected adults to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) versus continuing boosted PI-based triple regimens or dolutegravir/abacavir/lamivudine (DTG/ABC/3TC). Here, detailed analyses of pre-existing resistance in the two BIC/FTC/TAF switch studies and efficacy at week 48 are described.

Methods: Pre-existing resistance was assessed from historical genotypes (documented resistance to study drugs was excluded) and by retrospective baseline proviral archive DNA genotyping from whole blood. Outcomes were based on HIV-1 RNA at week 48 with missing values imputed using the last on-treatment observation carried forward method.

Results: Cumulative pre-existing resistance data from historical and proviral genotypes were obtained for 95% (543/570) of participants who switched to BIC/FTC/TAF. Altogether, 40% (217/543) had one or more pre-existing primary resistance substitutions in protease, reverse transcriptase and/or integrase. Pre-switch NRTI resistance was detected in 16% (89/543) of BIC/FTC/TAF-treated participants, with M184V or M184I detected by proviral genotyping in 10% (54/543). At week 48, 98% (561/570) of all BIC/FTC/TAF-treated participants versus 98% (213/217) with pre-existing resistance and 96% (52/54) with archived M184V/I had HIV-1 RNA <50 copies/mL. No BIC/FTC/TAF-treated participants developed treatment-emergent resistance to study drugs.

Conclusions: Pre-existing resistance substitutions, notably M184V/I, were unexpectedly common among suppressed participants who switched to BIC/FTC/TAF. High rates of virological suppression were maintained in the overall study population and in those with pre-existing resistance, including M184V/I, for up to 48 weeks of BIC/FTC/TAF treatment with no resistance development. These results indicate that BIC/FTC/TAF is an effective treatment option for suppressed patients, including those with evidence of archived NRTI resistance.

PubMed Disclaimer

References

    1. Saag MS, Benson CA, Gandhi RT. et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults - 2018 recommendations of the International Antiviral Society–USA Panel. JAMA 2018; 320: 379–96. - PMC - PubMed
    1. The Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
    1. Gallant JE, Thompson M, DeJesus E. et al. Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults. J Acquir Immune Defic Syndr 2017; 75: 61–6. - PMC - PubMed
    1. Tsiang M, Jones GS, Goldsmith J. et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother 2016; 60: 7086–97. - PMC - PubMed
    1. Mulato A, Acosta R, Yant SR. et al. Forgiveness of antiretroviral regimens: in vitro HIV-1 viral breakthrough with 2-drug versus 3-drug regimens simulating variable adherence to treatment [Poster 50]. In: 17th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, Rome, Italy.

Publication types

MeSH terms